These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872 [TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871 [TBL] [Abstract][Full Text] [Related]
4. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404 [TBL] [Abstract][Full Text] [Related]
5. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Cheer SM; Waugh J; Noble S Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360 [TBL] [Abstract][Full Text] [Related]
6. Microbiological and immunologic considerations with aerosolized drug delivery. LiPuma JJ Chest; 2001 Sep; 120(3 Suppl):118S-123S. PubMed ID: 11555566 [TBL] [Abstract][Full Text] [Related]
7. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection. Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995 [TBL] [Abstract][Full Text] [Related]
8. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Moss RB Chest; 2002 Jan; 121(1):55-63. PubMed ID: 11796432 [TBL] [Abstract][Full Text] [Related]
9. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Quittner AL; Buu A Pediatr Pulmonol; 2002 Apr; 33(4):269-76. PubMed ID: 11921456 [TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis. Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974 [TBL] [Abstract][Full Text] [Related]
12. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations. Al-Aloul M; Nazareth D; Walshaw M J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814 [TBL] [Abstract][Full Text] [Related]
13. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831 [TBL] [Abstract][Full Text] [Related]
14. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Geller DE; Rosenfeld M; Waltz DA; Wilmott RW; Chest; 2003 Jan; 123(1):28-36. PubMed ID: 12527599 [TBL] [Abstract][Full Text] [Related]
15. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641 [TBL] [Abstract][Full Text] [Related]
16. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Trapnell BC; McColley SA; Kissner DG; Rolfe MW; Rosen JM; McKevitt M; Moorehead L; Montgomery AB; Geller DE; Am J Respir Crit Care Med; 2012 Jan; 185(2):171-8. PubMed ID: 22095545 [TBL] [Abstract][Full Text] [Related]
17. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Murphy TD; Anbar RD; Lester LA; Nasr SZ; Nickerson B; VanDevanter DR; Colin AA Pediatr Pulmonol; 2004 Oct; 38(4):314-20. PubMed ID: 15334509 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization. van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357 [TBL] [Abstract][Full Text] [Related]
20. Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Prober CG; Walson PD; Jones J Pediatrics; 2000 Dec; 106(6):E89. PubMed ID: 11099632 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]